Please assess the completion status of the following clinical trial:

Trial Title: A Study of Safety and Efficacy of HPN-100 in Subjects With Cirrhosis and Episodic Hepatic Encephalopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects aged 18 and over~* Clinical diagnosis of cirrhosis of any cause~* Potential to benefit from HE treatment~* History of greater than or equal to 2 documented episodes of WH Grade 2 or more HE within the past 6 months, at least one of which occurred within the preceding 3 months~* No change in other HE-specific medications within 1 week before randomization~* Able to give informed consent and comply with study activities~* Availability of at least one designated family member or caregiver who is capable of and willing to assume responsibility for facilitating subject compliance with study procedures~* All females of childbearing age and all sexually active males must agree to use an acceptable method of contraception throughout the study.~Exclusion Criteria:~* Use of any investigational drug within 30 days~* Use of prohibited medications~* Uncontrolled infection~* Active GI bleeding or a history of GI bleeding requiring blood transfusion (\> 2 units) within 3 months~* Transjugular intrahepatic portosystemic shunt (TIPS) placement or revision within the past 90 days~* Recreational drug use or alcohol consumption for subjects with a history of alcohol or drug abuse within 6 months~* Lactating and/or pregnant females~* Active malignancy~* Clinically significant bowel disease, including obstruction, inflammatory bowel disease, or malabsorption~* Expected to undergo transplantation within 6 months~* Model for end-stage liver disease (MELD) score of \> 25

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HPN-100 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).